- Report
- October 2024
- 181 Pages
Global
From €3260EUR$3,545USD£2,758GBP
€3623EUR$3,939USD£3,064GBP
- Report
- February 2025
- 200 Pages
Global
From €4129EUR$4,490USD£3,493GBP
- Report
- April 2025
- 175 Pages
Global
From €4129EUR$4,490USD£3,493GBP
- Report
- April 2025
- 150 Pages
Global
From €4461EUR$4,850USD£3,773GBP
- Report
- July 2018
- 30 Pages
China
From €2023EUR$2,200USD£1,712GBP
- Report
- May 2024
- 131 Pages
Global
From €5977EUR$6,499USD£5,056GBP
- Report
- May 2024
- 137 Pages
Global
From €5977EUR$6,499USD£5,056GBP
- Report
- January 2022
- 60 Pages
Global
From €1380EUR$1,500USD£1,167GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9197EUR$10,000USD£7,780GBP
- Report
- July 2023
- 80 Pages
Global
From €3500EUR$4,077USD£3,064GBP
Epogen is a brand of hematological drug used to treat anemia caused by chronic kidney disease. It is a recombinant form of erythropoietin, a hormone produced by the kidneys that stimulates the production of red blood cells. Epogen is administered by injection or intravenous infusion and is used to increase the number of red blood cells in the body. It is also used to reduce the need for blood transfusions in patients with anemia due to chemotherapy or HIV infection.
Epogen is a widely used drug in the hematological market, and is often prescribed in combination with other drugs to treat anemia. It is also used to treat anemia in patients with cancer, HIV, and other conditions. The drug is available in both generic and brand-name forms.
Companies in the Epogen market include Amgen, Johnson & Johnson, Pfizer, and Novartis. Show Less Read more
